BACKGROUND: We conducted a meta-analysis to determine the effects of supervised exercise training on peak oxygen consumption (VO(2peak)) in adults with cancer. METHODS: A literature review using Ovid MEDLINE (1950-2010), the Cochrane Central Register of Controlled Trials (1991-2010), AMED (1985-2010), Embase (1988-2010), PubMed (1966-2010), Scopus (1950-2010), and Web of Science (1950-2010) was performed to identify randomized controlled trials examining the effects of supervised exercise training on measurement of VO(2peak) (via gas exchange analysis) in adults with cancer. Studies were selected using predetermined criteria, and two independent reviewers extracted data. Weighted mean differences (WMDs) were calculated using random effect models. RESULTS: Six studies evaluated VO(2peak) involving a total of 571 adult cancer patients (exercise, n = 344; usual care control, n = 227). Pooled data indicated that exercise training was associated with a statistically significant increase in VO(2peak) (WMD, 2.90 ml·kg(-1)·min(-1); 95% confidence interval [CI], 1.16-4.64); however, significant heterogeneity was evident in this estimate (I(2), 87%). Usual care (control) was associated with a significant decline in VO(2peak) from baseline to postintervention (WMD, -1.02 ml·kg(-1)·min(-1); 95% CI, -1.46 to -0.58; I(2), 22%). Sensitivity analyses indicated superior improvements in VO(2peak) for studies conducted for a shorter duration (<4 months) and following the completion of adjuvant therapy (p-values < .001). Exercise training was not associated with a higher incidence of adverse events, although safety was not rigorously monitored or reported. CONCLUSIONS: Supervised exercise training is associated with significant improvements in VO(2peak) following a diagnosis of early-stage cancer, with minimal adverse events.
BACKGROUND: We conducted a meta-analysis to determine the effects of supervised exercise training on peak oxygen consumption (VO(2peak)) in adults with cancer. METHODS: A literature review using Ovid MEDLINE (1950-2010), the Cochrane Central Register of Controlled Trials (1991-2010), AMED (1985-2010), Embase (1988-2010), PubMed (1966-2010), Scopus (1950-2010), and Web of Science (1950-2010) was performed to identify randomized controlled trials examining the effects of supervised exercise training on measurement of VO(2peak) (via gas exchange analysis) in adults with cancer. Studies were selected using predetermined criteria, and two independent reviewers extracted data. Weighted mean differences (WMDs) were calculated using random effect models. RESULTS: Six studies evaluated VO(2peak) involving a total of 571 adult cancerpatients (exercise, n = 344; usual care control, n = 227). Pooled data indicated that exercise training was associated with a statistically significant increase in VO(2peak) (WMD, 2.90 ml·kg(-1)·min(-1); 95% confidence interval [CI], 1.16-4.64); however, significant heterogeneity was evident in this estimate (I(2), 87%). Usual care (control) was associated with a significant decline in VO(2peak) from baseline to postintervention (WMD, -1.02 ml·kg(-1)·min(-1); 95% CI, -1.46 to -0.58; I(2), 22%). Sensitivity analyses indicated superior improvements in VO(2peak) for studies conducted for a shorter duration (<4 months) and following the completion of adjuvant therapy (p-values < .001). Exercise training was not associated with a higher incidence of adverse events, although safety was not rigorously monitored or reported. CONCLUSIONS: Supervised exercise training is associated with significant improvements in VO(2peak) following a diagnosis of early-stage cancer, with minimal adverse events.
Authors: Rebecca M Speck; Kerry S Courneya; Louise C Mâsse; Sue Duval; Kathryn H Schmitz Journal: J Cancer Surviv Date: 2010-01-06 Impact factor: 4.442
Authors: Jonathan Myers; Manish Prakash; Victor Froelicher; Dat Do; Sara Partington; J Edwin Atwood Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245
Authors: Kerry S Courneya; Christopher M Sellar; Clare Stevinson; Margaret L McNeely; Carolyn J Peddle; Christine M Friedenreich; Keith Tankel; Sanraj Basi; Neil Chua; Alex Mazurek; Tony Reiman Journal: J Clin Oncol Date: 2009-08-17 Impact factor: 44.544
Authors: Lee W Jones; Pamela S Douglas; Neil D Eves; P Kelly Marcom; William E Kraus; James E Herndon; Brant A Inman; Jason D Allen; Jeffrey Peppercorn Journal: BMC Cancer Date: 2010-10-06 Impact factor: 4.430
Authors: Lis Adamsen; Morten Quist; Christina Andersen; Tom Møller; Jørn Herrstedt; Dorte Kronborg; Marie T Baadsgaard; Kirsten Vistisen; Julie Midtgaard; Birgitte Christiansen; Maria Stage; Morten T Kronborg; Mikael Rørth Journal: BMJ Date: 2009-10-13
Authors: James L Devin; Andrew T Sax; Gareth I Hughes; David G Jenkins; Joanne F Aitken; Suzanne K Chambers; Jeffrey C Dunn; Kate A Bolam; Tina L Skinner Journal: J Cancer Surviv Date: 2015-10-19 Impact factor: 4.442
Authors: Daniel Niederer; Lutz Vogt; Javier Gonzalez-Rivera; Katharina Schmidt; Winfried Banzer Journal: Support Care Cancer Date: 2015-04-03 Impact factor: 3.603
Authors: D Santa Mina; D Au; J Brunet; J Jones; G Tomlinson; N Taback; D Field; A Berlingeri; H Bradley; D Howell Journal: Curr Oncol Date: 2017-10-25 Impact factor: 3.677
Authors: Jessica M Scott; Aarif Khakoo; John R Mackey; Mark J Haykowsky; Pamela S Douglas; Lee W Jones Journal: Circulation Date: 2011-08-02 Impact factor: 29.690